Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RNA Avidity Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: RNA
Price (delayed)
$28.69
Market cap
$3.45B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$3.23B
Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in
Highlights
Avidity Biosciences's debt has decreased by 31% YoY and by 11% from the previous quarter
The gross profit rose by 14% YoY and by 8% QoQ
The equity has soared by 185% YoY but it fell by 5% QoQ
RNA's quick ratio has soared by 108% YoY but it is down by 12% from the previous quarter
RNA's net income has shrunk by 52% YoY and by 15% QoQ
Key stats
What are the main financial stats of RNA
Market
Valuations
Earnings
Shares outstanding
120.21M
Market cap
$3.45B
Enterprise value
$3.23B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.4
Price to sales (P/S)
293.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
296.69
Revenue
$10.9M
Gross profit
$10.9M
Operating income
-$378.94M
Net income
-$322.3M
EBIT
-$322.3M
EBITDA
-$316.23M
Free cash flow
-$307.94M
Per share
Balance sheet
Liquidity
EPS
-$2.89
EPS diluted
-$2.89
Free cash flow per share
-$2.76
Book value per share
$11.94
Revenue per share
$0.1
TBVPS
$14.02
Total assets
$1.56B
Total liabilities
$138.94M
Debt
$6.8M
Equity
$1.42B
Working capital
$1.44B
Debt to equity
0
Current ratio
15.73
Quick ratio
15.35
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-2,902%
Gross margin
100%
Net margin
-2,957.7%
Operating margin
-3,477.4%
Return on assets
-23.4%
Return on equity
-25.9%
Return on invested capital
-36.4%
Return on capital employed
-22%
Return on sales
-2,957.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNA stock price
How has the Avidity Biosciences stock price performed over time
Intraday
9.63%
1 week
-12.24%
1 month
19.14%
1 year
10.09%
YTD
-1.34%
QTD
-2.81%
Financial performance
How have Avidity Biosciences's revenue and profit performed over time
Revenue
$10.9M
Gross profit
$10.9M
Operating income
-$378.94M
Net income
-$322.3M
Gross margin
100%
Net margin
-2,957.7%
The operating income has plunged by 61% YoY and by 17% from the previous quarter
RNA's net income has shrunk by 52% YoY and by 15% QoQ
RNA's operating margin is down by 41% year-on-year and by 8% since the previous quarter
Avidity Biosciences's net margin has decreased by 33% YoY and by 7% from the previous quarter
Price vs fundamentals
How does RNA's price correlate with its fundamentals
Growth
What is Avidity Biosciences's growth rate over time
Valuation
What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
2.4
P/S
293.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
296.69
The equity has soared by 185% YoY but it fell by 5% QoQ
The P/B is 17% below the last 4 quarters average of 2.9
RNA's P/S is 91% above its 5-year quarterly average of 154.2 but 20% below its last 4 quarters average of 368.7
RNA's revenue is up by 14% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Avidity Biosciences business performance
The ROE has grown by 35% YoY and by 6% from the previous quarter
RNA's ROS is down by 33% YoY and by 7% from the previous quarter
RNA's ROA is up by 33% YoY and by 4.9% from the previous quarter
RNA's return on invested capital is up by 27% year-on-year and by 14% since the previous quarter
Dividends
What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNA.
Financial health
How did Avidity Biosciences financials performed over time
RNA's total assets has soared by 149% YoY but it is down by 4.7% QoQ
RNA's quick ratio has soared by 108% YoY but it is down by 12% from the previous quarter
Avidity Biosciences's debt is 100% less than its equity
The equity has soared by 185% YoY but it fell by 5% QoQ
Avidity Biosciences's debt to equity has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.